Literature DB >> 1649577

Activity of mersacidin, a novel peptide, compared with that of vancomycin, teicoplanin, and daptomycin.

W W Niu1, H C Neu.   

Abstract

Mersacidin, a new peptide antibiotic, was four- to eightfold less active (MIC for 90% of isolates, 8 micrograms/ml) than vancomycin, teicoplanin, or daptomycin against Staphylococcus aureus. Coagulase-negative staphylococci were inhibited by 8 micrograms/ml, and the MICs of mersacidin for hemolytic streptococci and Streptococcus pneumoniae were 4 to 8 micrograms/ml. The mersacidin MICs for anaerobic organisms were as follows: Clostridium perfringens, 4 micrograms/ml; Propionibacterium acnes, 8 micrograms/ml; peptococci, 1 microgram/ml; and peptostreptococci, 8 micrograms/ml. Mersacidin had no activity against members of the family Enterobacteriaceae, Neisseria and Haemophilus species, or Pseudomonas aeruginosa. The size of the inoculum, the pH of the assay (5.5 to 7.5), the type of medium, and the anaerobic conditions had minimal effects on the MICs and MBCs of mersacidin. Overall, mersacidin proved less active than available glycopeptides and peptolides.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649577      PMCID: PMC245145          DOI: 10.1128/AAC.35.5.998

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

Review 1.  Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures.

Authors:  J M Boyce
Journal:  Infect Dis Clin North Am       Date:  1989-12       Impact factor: 5.982

Review 2.  Coagulase-negative staphylococci. Epidemiology, evaluation, and therapy.

Authors:  D A Nafziger; R P Wenzel
Journal:  Infect Dis Clin North Am       Date:  1989-12       Impact factor: 5.982

Review 3.  The epidemiology of enterococci.

Authors:  C Chenoweth; D Schaberg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-02       Impact factor: 3.267

4.  Method of reliable determination of minimal lethal antibiotic concentrations.

Authors:  R D Pearson; R T Steigbigel; H T Davis; S W Chapman
Journal:  Antimicrob Agents Chemother       Date:  1980-11       Impact factor: 5.191

  4 in total
  13 in total

Review 1.  Clinical pharmacokinetics of teicoplanin.

Authors:  A P Wilson
Journal:  Clin Pharmacokinet       Date:  2000-09       Impact factor: 6.447

2.  Cell Wall-active Bacteriocins and Their Applications Beyond Antibiotic Activity.

Authors:  Clara Roces; Ana Rodríguez; Beatriz Martínez
Journal:  Probiotics Antimicrob Proteins       Date:  2012-12       Impact factor: 4.609

3.  Activity of gallidermin on Staphylococcus aureus and Staphylococcus epidermidis biofilms.

Authors:  Jongkon Saising; Linda Dube; Anne-Kathrin Ziebandt; Supayang Piyawan Voravuthikunchai; Mulugeta Nega; Friedrich Götz
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

Review 4.  Bacteriocins - a viable alternative to antibiotics?

Authors:  Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Nat Rev Microbiol       Date:  2012-12-24       Impact factor: 60.633

Review 5.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

6.  Comparison of the Potency of the Lipid II Targeting Antimicrobials Nisin, Lacticin 3147 and Vancomycin Against Gram-Positive Bacteria.

Authors:  Catalin Iancu; Aoife Grainger; Des Field; Paul D Cotter; Colin Hill; R Paul Ross
Journal:  Probiotics Antimicrob Proteins       Date:  2012-06       Impact factor: 4.609

7.  Comparative In vitro activities of daptomycin and vancomycin against resistant gram-positive pathogens.

Authors:  D R Snydman; N V Jacobus; L A McDermott; J R Lonks; J M Boyce
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 8.  Anti-infective treatment in intensive care: the role of glycopeptides.

Authors:  R N Grüneberg; A P Wilson
Journal:  Intensive Care Med       Date:  1994-11       Impact factor: 17.440

9.  Mode of action of the lantibiotic mersacidin: inhibition of peptidoglycan biosynthesis via a novel mechanism?

Authors:  H Brötz; G Bierbaum; A Markus; E Molitor; H G Sahl
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

Review 10.  Teicoplanin. A reappraisal of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  R N Brogden; D H Peters
Journal:  Drugs       Date:  1994-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.